Anuh Pharma (506260) Q3 24/25 earnings summary

Executive summary

• Unaudited financial results for the quarter and nine months ended 31 December 2024 were reviewed and approved by the Board on 7 February 2025.

• Statutory auditors conducted a limited review and found no material misstatements.

Financial highlights

• Revenue from operations for Q3 FY25 was Rs 15,951.33 lakh, down from Rs 17,210.13 lakh in Q3 FY24.

• Net profit after tax for Q3 FY25 stood at Rs 1,034.31 lakh, compared to Rs 1,911.31 lakh in Q3 FY24.

• For the nine months ended 31 December 2024, revenue was Rs 47,143.24 lakh and net profit after tax was Rs 3,489.49 lakh.

• EBITDA for Q3 FY25 was Rs 1,572.71 lakh (margin 9.86%), down from Rs 2,764.94 lakh (margin 16.07%) in Q3 FY24.

• Basic and diluted EPS for Q3 FY25 were Rs 2.06, compared to Rs 3.81 in Q3 FY24.

Outlook and guidance

• The company completed a strategic investment of Rs 115.50 lakh in Houban Energy 5 Private Limited in November 2024.